Versailles Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rousselot, Philippe
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
NCT05753384: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Recruiting
3
140
Europe
treatment of TKI in CML
Poitiers University Hospital
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia
12/28
12/29
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
IMAGE-19, NCT04357613: IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.

Not yet recruiting
2
99
Europe
Experimental drug
Versailles Hospital
SARS Virus
12/20
12/21
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR

Recruiting
1/2
100
Europe
Pioglitazone, Avelumab
Versailles Hospital
Leukemia, Myeloid, Chronic-Phase
11/22
06/23
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
12/26
12/26
EPIK, NCT03481868: EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Recruiting
N/A
160
Europe
Collection of blood and bone marrow
University Hospital, Clermont-Ferrand, Institut Paoli-Calmettes, CHRU Lille, hematology department, CH Annecy Genevois, Institut Bergonié Bordeaux, hematology department, CHU Nancy, hematology department, CHU Saint-Etienne, hematology department, Institut Universitaire du Cancer de Toulouse - Oncopole, hematology department, CHU Caen, hematology department, CHU Nice, hematology department, CHU Lyon, hematology department, AP-HP, hematology department, AP-HP Hôpital Henri-Mondor, hematology department, Versailles Hospital, Centre Leon Berard, University Hospital, Grenoble
Chronic Myeloid Leukemia (CML), Chronic Phase
05/25
02/26
BIO-TIMER, NCT06130787: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Recruiting
N/A
321
Europe
Blood and bone marrow sample
University Hospital, Clermont-Ferrand
Leukemia,Myeloid, Chronic
11/25
11/28
NCT05963061: Chronic Myeloid Leukemia (CML) Real-Life Database

Recruiting
N/A
3500
Europe
University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire de Saint Etienne, Bicetre Hospital, University Hospital, Caen, Central Hospital, Nancy, France, University Hospital, Toulouse, CH Annecy Genevois, Rennes University Hospital, Hopital Paul Brousse, Versailles Hospital, Centre Hospitalier Emile Roux, University Hospital, Limoges, Institut Paoli-Calmettes, Centre Hospitalier de Rochefort
Chronic Myeloid Leukemia (CML)
04/34
04/34
LEGRIEL, Stéphane
PLATINIUM, NCT06774235: Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

Not yet recruiting
3
326
Europe
Interferon Gamma 1-b, Placebo
University Hospital, Limoges
Sustained Immunosuppression
09/28
09/28
AfterROSC1, NCT04167891: Comparison of Scores for Early Brain Damage Assessment at Intensive Care Unit Admission After Out of Hospital Cardiac Arrest

Completed
N/A
1144
Europe
Calculation of early prognosis score
AfterROSC
Cardiac Arrest
06/22
09/23
POSEIDON2, NCT06100978: Patient-reported Outcome and Patient-reported Experience After Status Epilepticus

Recruiting
N/A
145
Europe
Versailles Hospital
Patient Reported Outcomes, Patient Satisfaction, Long Term Outcomes, Status Epilepticus, Intensive Care Unit, Burden, Relatives
05/25
07/26

Download Options